BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–100 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF Mutation7
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6305 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6306 This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salv… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID1704 A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xeno… (full text at CIViC) PMID 22586653 · Bertotti et al., 2011 · Open in CIViC	civic
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2187 This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were K… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1404 A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targ… (full text at CIViC) PMID 25673558 · Pietrantonio et al., 2015 · Open in CIViC	civic
Irinotecan	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6304 This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It as… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Oxaliplatin	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6303 This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antib… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF V600E24
Bevacizumab + Capecitabine + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2121 In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=… (full text at CIViC) PMID 19571295 · Tol et al., 2009 · Open in CIViC	civic
Binimetinib + Cetuximab + EncorafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID7260 In a phase III trial, patients with BRAF V600E mutated metastatic colorectal cancer received triplet combination with encorafenib + binimetinib + cetuximab in a second or third-line setting. In the sa… (full text at CIViC) Open in CIViC	civic
BRAF D594G3
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Does Not Support Resistance	3	accepted	EID2201 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PI… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID4472 In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to b… (full text at CIViC) PMID 26989027 · Hsu et al., 2016 · Open in CIViC	civic
Cetuximab
BRAF V6006
Cetuximab + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1598 Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with B… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID1415 In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed partia… (full text at CIViC) PMID 26392102 · Corcoran et al., 2015 · Open in CIViC	civic
BRAF K601E + BRAF V600E1
Cobimetinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11670 This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC) PMID 36409971 · Klute et al., 2022 · Open in CIViC	civic
BRAF D594K2
Irinotecan	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6402 The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Oxaliplatin	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID6403 Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
BRAF Amplification1
Dabrafenib + PanitumumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2929 Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant … (full text at CIViC) PMID 25673644 · Ahronian et al., 2015 · Open in CIViC	civic
BRAF G466V2
Irinotecan + PanitumumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID7552 In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells o… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7553 In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells … (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF Amplification + BRAF V600E1
Selumetinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	E	Supports Resistance	4	accepted	EID92 COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC) PMID 21098728 · Corcoran et al., 2010 · Open in CIViC	civic
BRAF G596R1
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	1	accepted	EID4729 In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing muta… (full text at CIViC) PMID 22180495 · Yang et al., 2012 · Open in CIViC	civic
ARAF S490T + BRAF V600EBRAF ARAF1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID1905 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
BRAF V600E + GNAS R201CBRAF GNAS1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1906 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

emaRegulatory8 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Vemurafenib	EU EMA	Melanoma	Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.	approved	Feb 17, 2012	ema
Vemurafenib	US FDA	—	Efficacy supplement 2017-11-06 (see label)	approved	Nov 6, 2017	openfda
Vemurafenib	US FDA	—	Efficacy supplement 2017-09-13 (see label)	approved	Sep 13, 2017	openfda
Vemurafenib	US FDA	—	Efficacy supplement 2016-08-31 (see label)

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 501–550 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05265208	Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer(SIROCHO)	recruiting	Phase 2	62	Center Eugene MarquisOTHER	1	Aug 6, 2025	clinicaltrials
NCT06856187	Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer(TASBEL)	recruiting	Phase 2	119	Fudan UniversityOTHER	1	Aug 6, 2025	clinicaltrials
NCT03493048	Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM	active not recruiting	Phase 2	146	Sun Yat-sen UniversityOTHER	1	Aug 3, 2025	clinicaltrials
NCT05442060	To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer(EGFR)	recruiting	Phase 2	60	OBI Pharma, IncINDUSTRY	1	Aug 3, 2025	clinicaltrials
NCT02304809	Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations(AcSé)	active not recruiting	Phase 2	216	UNICANCEROTHER	1	Aug 1, 2025	clinicaltrials
NCT06441565	Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer	recruiting	Phase 2 / Phase 3	84	Sun Yat-sen UniversityOTHER	1	Jul 30, 2025	clinicaltrials
NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling(ProTarget)	recruiting	Phase 2	300	Ulrik LassenOTHER	1	Jul 25, 2025	clinicaltrials
NCT06208410	A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors	recruiting	Phase 1 / Phase 2	306	Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY	1	Jul 25, 2025	clinicaltrials
NCT05755672	On-treatment Biomarkers in Metastatic Colorectal Cancer for Life(On-CALL)	recruiting	—	100	Region SkaneOTHER	1	Jul 17, 2025	clinicaltrials
NCT07071844	BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients(BETWEEN)	not yet recruiting	Phase 2	162	GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER	1	Jul 17, 2025	clinicaltrials
NCT07062263	Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2)	recruiting	Phase 3	220	Tata Memorial CentreOTHER	1	Jul 14, 2025	clinicaltrials
NCT07035392	Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC	not yet recruiting	Phase 2	32	Zhangzhou Municipal HospitalOTHER	0	Jun 25, 2025	clinicaltrials
NCT06885385	A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer	recruiting	Phase 2	60	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Jun 24, 2025	clinicaltrials
NCT06954584	Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer	recruiting	Phase 3	424	Tongji HospitalOTHER	1	Jun 24, 2025	clinicaltrials
NCT07025239	QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer	not yet recruiting	Phase 3	430	Qilu Pharmaceutical Co., Ltd.INDUSTRY	0	Jun 17, 2025	clinicaltrials
NCT05118724	Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin(ANTONIO)	active not recruiting	Phase 2	80	AIO-Studien-gGmbHOTHER	1	Jun 15, 2025	clinicaltrials
NCT07021950	AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer	not yet recruiting	Phase 2	130	Sun Yat-sen UniversityOTHER	0	Jun 15, 2025	clinicaltrials
NCT07009145	QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC	not yet recruiting	Phase 2	22	Qianfoshan HospitalOTHER	1	Jun 6, 2025	clinicaltrials
NCT06943820	AK129 Combination Therapy for Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	230	AkesoINDUSTRY	1	Jun 3, 2025	clinicaltrials
NCT03390686	A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients	active not recruiting	Phase 3	650	Prestige Biopharma LimitedINDUSTRY	17	May 31, 2025	clinicaltrials
NCT04861558	Efficacy of Hyperthermic Intraperitoneal Chemotherapy(EFFIPEC)	recruiting	Phase 3	213	Uppsala UniversityOTHER	2	May 30, 2025	clinicaltrials
NCT05704985	Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors	active not recruiting	Phase 1	39	DEKA BiosciencesINDUSTRY	1	May 29, 2025	clinicaltrials
NCT04043195	Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC(NSCLC)	active not recruiting	Phase 1 / Phase 2	30	Hatim HusainOTHER	1	May 28, 2025	clinicaltrials
NCT05312398	CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen	active not recruiting	Phase 2	219	University of Campania Luigi VanvitelliOTHER	1	May 25, 2025	clinicaltrials
NCT06990503	SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer	not yet recruiting	Phase 3	300	Tongji HospitalOTHER	1	May 25, 2025	clinicaltrials
NCT06990516	SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer	not yet recruiting	Phase 1 / Phase 2	90	Tongji HospitalOTHER	1	May 25, 2025	clinicaltrials
NCT04941287	Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer	active not recruiting	Phase 2	57	National Cancer Institute (NCI)NIH	1	May 23, 2025	clinicaltrials
NCT06975917	Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)(TOG-SAFRADJU)	active not recruiting	—	600	Ankara UniversityOTHER	1	May 16, 2025	clinicaltrials
NCT06381570	Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas(VICTORY)	recruiting	Early Phase 1	57	Daniel MorgensternOTHER	1	May 15, 2025	clinicaltrials
NCT03673787	A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP)	active not recruiting	Phase 1 / Phase 2	87	Institute of Cancer Research, United KingdomOTHER	1	May 14, 2025	clinicaltrials
NCT06963502	A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors	not yet recruiting	Phase 1	762	Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY	1	May 9, 2025	clinicaltrials
NCT06962267	A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)	recruiting	Phase 2	50	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY	1	May 8, 2025	clinicaltrials
NCT06090994	Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy	recruiting	Phase 4	756	Fudan UniversityOTHER	1	May 7, 2025	clinicaltrials
NCT06944587	A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer(NORPACT-3)	recruiting	—	400	Oslo University HospitalOTHER	1	Apr 25, 2025	clinicaltrials
NCT05342194	Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study	recruiting	Phase 3	480	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Apr 23, 2025	clinicaltrials
NCT06895928	A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors	recruiting	Phase 2	400	Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY	1	Apr 22, 2025	clinicaltrials
NCT04775485	A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1)	recruiting	Phase 2	141	Day One Biopharmaceuticals, Inc.INDUSTRY	11	Apr 10, 2025	clinicaltrials
NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE)	not yet recruiting	Phase 1 / Phase 2	221	Xynomic Pharmaceuticals, Inc.INDUSTRY	0	Apr 10, 2025	clinicaltrials
NCT05255302	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL)	recruiting	Phase 2 / Phase 3	1,360	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Apr 1, 2025	clinicaltrials
NCT02170090	Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer(ACTICCA-1)	active not recruiting	Phase 3	789	Universitätsklinikum Hamburg-EppendorfOTHER	8	Mar 30, 2025	clinicaltrials
NCT06888843	Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.(AHTCRR-1)	recruiting	Phase 2	160	Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV	1	Mar 27, 2025	clinicaltrials
NCT05828459	First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors	recruiting	Phase 1	150	Onward TherapeuticsINDUSTRY	1	Mar 20, 2025	clinicaltrials
NCT06560112	An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer	recruiting	Phase 2	172	AkesoINDUSTRY	1	Mar 12, 2025	clinicaltrials
NCT06866977	A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer	not yet recruiting	Phase 1 / Phase 2	10	Xiangya Hospital of Central South UniversityOTHER	1	Mar 10, 2025	clinicaltrials
NCT05704621	Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance(SOCCER-P)	recruiting	Phase 2	124	Korea University Guro HospitalOTHER	1	Mar 6, 2025	clinicaltrials
NCT06856447	The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer	recruiting	Phase 1	22	toqa saad mohammed mohammedOTHER	1	Mar 4, 2025	clinicaltrials
NCT06208462	Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors	recruiting	Phase 2	33	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	1	Mar 3, 2025	clinicaltrials
NCT06849362	Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer	enrolling by invitation	—	200	Yue GouOTHER	1	Feb 27, 2025	clinicaltrials
NCT06825624	ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer	recruiting	Phase 1	560	Hansoh BioMedical R&D CompanyINDUSTRY	1	Feb 13, 2025	clinicaltrials
NCT05200260	Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer	recruiting	Phase 2	220	Shanghai Gynecologic Oncology GroupOTHER_GOV	1	Feb 10, 2025	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)